Loxo Oncology, Inc.
Clinical trials sponsored by Loxo Oncology, Inc., explained in plain language.
Cancer-focused biotech acquired by Eli Lilly.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New hope in blood cancer battle: Next-Gen drug tested against standard therapy
Disease control Recruiting nowThis study tests whether a newer drug called pirtobrutinib works better than the current standard drug ibrutinib for people with chronic lymphocytic leukemia or small lymphocytic lymphoma. About 737 adults who need treatment for their cancer will be randomly assigned to receive o…
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for Tough-to-Treat blood cancers: pirtobrutinib trial launches
Disease control Recruiting nowThis study tests three different doses of a drug called pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer came back or didn't respond after treatment with a BTK inhibitor. About 249 participants will take part. The go…
Phase: PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC